Financings In Brief: IDEC Pharmaceuticals
Executive Summary
IDEC Pharmaceuticals: Net proceeds from 2.1 mil. share offering approximate $46 mil., the company announces June 12. The offering, consisted of 1.8 mil. shares plus an additional 270,000 shares in an over-allotment which underwriters Morgan, Stanley and Punk, Ziegel & Knoell exercised in full. Proceeds will be used to support development of the company's immune system products for the treatment of cancers, autoimmune and inflammatory diseases...